BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

P2D Bioscience Announces Enhanced Patent Position for Lead ADHD Drug


4/26/2011 11:47:41 AM

CINCINNATI and Mumbai, India – April 26, 2011 – P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead compounds, PD2005 and PD2007, have received U.S. and Canadian patent protection for treating Attention Deficit/Hyperactivity Disorder (ADHD). The patents contain ADHD-use claims for the entire family of P2D’s first-in-class dopamine transport inhibitors, including PD2005 and PD2007.

Initial studies indicate that P2D’s lead compounds are as effective as current first-line ADHD treatments in preclinical ADHD models. Additionally, preclinical studies indicate that P2D’s lead compounds demonstrate reduced side effects, the primary criticism of existing first-line treatments.

“Securing U.S. and Canadian use patent protection is a significant step forward in the development of our ADHD drugs, and it complements our exclusive license for the composition of matter patent for these compounds,” said Dr. Frank Zemlan, CEO of P2D. “We are focused on developing novel drug treatments that meet the needs of parents and children who are concerned about the side effects of today’s popular ADHD treatments. Early studies indicate that our lead compounds demonstrate similar efficacy as current ADHD first-line medications without the side effects. We believe that the combination of P2D’s improved patent position and preclinical studies demonstrating robust efficacy and limited side effects places us in a strong position to develop a novel safe and effective ADHD treatment.”

In addition to U.S. and Canadian patents, patent protection for P2D’s family of ADHD compounds is being prosecuted internationally.

About P2D Bioscience (P2D, Inc.)

P2D Bioscience is a privately held biopharmaceutical company focused on developing treatments for central nervous system and pulmonary diseases. P2D is developing first-in-class treatments for these disorders using novel proprietary chemical compounds. For example, its ADHD dopamine transporters are tropane analogs structurally different from current first-line ADHD drug treatments, amphetamine and methylphenidate. Additional information about P2D products in development may be found at www.p2dinc.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES